Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat

Pharmacology

Volumn 54, Issue 1, 1997, Pages 24-32

  Feuerstein, Giora Z ^a   Fisher, Marc ^b   Nunnari, J ^b   Ruffolo, Robert R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Carvedilol; Hypercholesterolemia; Nifedipine; Blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHOLESTEROL; LIPID; NIFEDIPINE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; FOAM CELL; HYPERCHOLESTEROLEMIA; LIPID STORAGE; MALE; MONOCYTE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0031052823     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139466     Document Type: Article

References (33)

1. Ruffolo RR. Bovlc DA. Brooks DP. Feuerstein G. Venuti RP. Lukas MA. Poste G: Carvedilol: A novel cardiovascular ding with multiple actions. Cardiovasc Drug Rev 1992: 10:127-157.
2. Sponer G. Strein K. Bartsch W, Mullcr-Beckmann B: Vasodilatorv action of carvcdilol. J Cardiovasc Pharmacol 1992; 19(suppl 1):S5-S11.
3. DasGupta P, Broadhurst P, Raferty F.B. Lahiri A: Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990:66:1118-1123.
4. Hall S. Prescott RI. Hallman RJ, Dixon S. Harvey RE. Ball SG: A comparative study of carvedilol, low-release nifedipine, and atenolol in the management of essential hypertension. J Cardiovasc Pharmacol 1991; 18(suppl 4):S35-S38.
5. Goto Y. Tamachi H. Fusegawa Y. Nakaya N. Homma Y. Mikami M. lori S. Yamazaki A: Effects of carvedilol on serum lipids in patients with essential hypertension. J Cardiovasc Pharmacol 1991; 18(suppl 4):S45-S50.
6. Scguchi H, Nakamura H. Aosaki N. Homma Y, Mikami Y. Takahashi S: Effects of carvedilol on scrum lipids in hypertensive and normotensive subjects. Eur J Clin Pharmacol 1990;38: S139-S142.
7. Yue T-L, McKenna PJ. Lysko PG. Ruffolo RR. Feuerstein G: Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 1992:97:209-216.
8. Yue T-L. Liu T, Feuerstein G: Carvcdilol. A new vasodilator and ß-adre-noceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun 1992;1:27-35.
9. Yue T-L. Cheng H-Y. Lysko PG. McKenna PF. Feurstcin R. Gu J-L. Lysko KA, Davis LL, Feuerstein G: Carvedilol. A new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992: 263:92-98.
10. Ohlstein EH. Douglas SA. Sung CP. Yue T-L, Louden C. Arleth Y. Poste G, Ruffolo RR. Feuerstein G: Carvedilol. A cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointi-mal formation following vascular injury. Proc Natl Acad Sei USA 1993: 90:6189-6193.
11. Sung C-P, Arleth AJ, Ohlstein EH: Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardio-vasc Pharmacol 1993:21:221-227.
12. Hashimoto H, Kanda A. Hubo H, Tanaka M: Features of the acute hypotensive action of carvedilol and its ameliorating effect on myocardial ischemia. J Cardiovasc Pharmacol 1991:18(suppl 4):S22-S28.
13. lamburger SA, Barone FC, Feuerstein G. Ruffolo RR: Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology 1991:43: 113-120.
14. Bril A. Slivjak M. DiMartino MJ. Feuerstein GZ, Linee P, Poyser RH. Ruffolo RR. Smith EF: Cardioprotective effects of carvedilol. A novel ß adrenoceptor antagonist with vasodilating properties, in anesthetized minipigs: Comparison with propranolol. Cardiovasc Res 1992; 26:518-525.
15. Smith EF. Griswold DE. Hillcgass LM, Slivjak MJ. Davis PA, DiMartino MJ: Cardioprotective effects of the vasodilator/bcta-adrcnoceptor blocker, carvedilol, in two models of myocardial infarction in the rat. Pharmacology 1992;44:297-305.
16. Feuerstein G, Hamburger S, Smith EF, Bril A, Ruffolo RR: Myocardial protection with carvedilol. J Cardiovasc Pharmacol 1992;19(suppl 1):S138-S141.
17. Lysko PG. Lysko C, Webb CL, Feuerstein G: Neuroprotcctive effects of carvedilol, a new antihypertensive. at the N-methvl-D-aspartate receptor. Neurosci Lett 1992:148: 34-38.
18. Lysko PG. Lysko C. Yue T-L. Webb CL, Gu J-L. Feuerstein G: Neuroprotcctive effects of carvedilol. A new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 1992:23:1630-1636.
19. Henry P: Calcium antagonists as antiatherogenic agents; in Vanhoutte PM. Poletti R, Govoni S (eds): Calcium Antagonists. Pharmacology and Clinical Research. New York. NY Academy of Science. 1988, vol 522, p 411.
20. Nunnari JJ, Fisher M, White SDT: Inhibition of lipid deposition in the hypercholestcrolemic rat by clentia-zem. A calcium channel blocker. Exp Mol Pathol 1992;57:193-204.
21. ILAR. NRC: Guide for the Care and Use ofLaboratory Animals. DHEW Publication No. NIH 78-23. 1985.
22. Nunnari JJ. Zand T, Juris I. Majno G: Quantitation of oil red O staining of the aorta in hypercholestcrolemic rats. Exp Mol Pathol 1989:51:1-8.
23. Joris I, Zand T, Nunnari JJ. Kroli-kowski F. Majno G: Studies on the pathogenesis of atherosclerosis. 1. Adhesion and emigration ofmono-cuclear cells in the aorta of hyper-cholesterolemic rats. Am J Pathol 1983;1 13:341-358.
24. Whittington-Coleman PJ. Carrier O, Douglas BH: The effects of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis 1973;18:337-345.
25. Chobanian AV, Brechcr P, Chan C: Etfects of propranolol on atherogen-esis in the cholesterol-fed rabbit. CircRes 1985:56:755-762.
26. Ostlund-Lindqvist AM. Lindqvist P. Brautigam J, Olsson G. Bondjers G. Nordborg C: Effect of meto-prololon diet-induced atherosclerosis in rabbits. Arteriosclerosis 1988: 8:40-45.
27. Pick R. Glick G: Etfects of propranolol, minoxidil, and elofibrate on cholesterol-induced atherosclerosis in stumptail macaques (Macaco arc-toidcs). Atherosclerosis 1977:27:71-77.
28. Kaplan JR. Manuck SB, Adams MR, Weingand KW, Clarkson TB: Inhibition of coronary atherosclerosis by propranolol in bchaviorally predisposed monkeys fed an atherogenic diet. Circulation 1987:76: 1364-1372.
29. Paulctto P. Pessina AC, Thicnc PG, Sempliani A. Vescoro G, Mazzucato A, Scannapieco G, Angelini A, Dal Palù C: Evidence of reduced atherosclerotic lesions in broad breasted white turkeys treated with oxpreno-lol. Artery 1983:12:220-233.
30. Orekhov AN. Andrianova IV, Rekhtcr MD. Tcrtov VV. Andreeva ER, Ragimov SE. Mironov AA: Beta-blockers: Propranolol, meto-prolol. atenolol, pindalol, alpreno-lol. and timolol manifest athcrogen-icity on in vitro, ex vivo and in vivo models. Elimination of propranolol atherogenic effects by papaverine. Atherosclerosis 1992:95:77-85.
31. Nunnari JJ, White SDT, Cuenoud HFC: The effects of fclodipinc on lipid deposition in the rat aorta. Circulation 1993:88:1522.
32. Camejor G, Hurt E. Thubrikar M, Bondjers G: Modification of low density lipoprotein association with the arterial intima, a possible environment for the anti-atherogenic action of p-blockers. Circulation 1991; 84(suppl V1):VI17-VI22.
33. Frostegard J, Nilsson J, Haeger-strand A. Hamstcn A, Wigzell H. Gidlund M: Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990:87: 904-908.